Cocrystal Pharma, Inc.
135.3M
$15.48M
-1.25
$-0.78
No price alerts set. Add an alert to get notified!
-1.25
1.75
$-0.78
-139.49%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$4.29 | -4.88% | -0.24 | $8.24M | 0.87 |
|
BRTX
BioRestorative Therapies, Inc.
|
$0.28 | -2.46% | -0.17 | $2.50M | 0.00 |
|
CING
Cingulate Inc.
|
$6.14 | 2.16% | -1.49 | $34.42M | 3.50 |
|
DWTX
Dogwood Therapeutics, Inc.
|
$2.11 | -0.94% | -0.89 | $4.03M | 0.00 |
|
EVGN
Evogene Ltd.
|
$0.78 | -3.39% | -0.82 | $6.81M | -26.80 |
|
IMNN
Imunon, Inc.
|
$3.22 | 7.69% | -0.47 | $8.12M | 0.14 |
|
IMRN
Immuron Limited
|
$0.80 | -0.74% | -1.65 | $5.16M | 0.00 |
|
MRKR
Marker Therapeutics, Inc.
|
$1.32 | 0.76% | -1.66 | $14.25M | 0.00 |
|
SNSE
Sensei Biotherapeutics, Inc.
|
$31.02 | -10.84% | -1.85 | $39.14M | 0.08 |
|
TRAW
Traws Pharma, Inc.
|
$1.64 | -1.20% | -1.05 | $7.82M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$2.67
$0.86
$0.00
0.00%
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
